Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders October 28, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors October 23, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences August 28, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study August 19, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update August 08, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day July 08, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 June 27, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis June 14, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces Leadership Team Promotions May 30, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference May 30, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease May 21, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering May 16, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants May 15, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer May 02, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update March 14, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor March 11, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences January 31, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 January 08, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference November 21, 2023 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update November 09, 2023 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases November 07, 2023 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences October 27, 2023 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules October 26, 2023 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors October 17, 2023 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases October 17, 2023 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update August 10, 2023 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors July 26, 2023 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases May 23, 2023 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Tickers GLUE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
